Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Investors usually focus on stocks that already have stellar dividend yields, but your portfolio could also benefit from ...

(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy ® (semaglutide), which includes ...

Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

The Children’s Investment Fund Foundation (CIFF) committed US$ 13 million and pledged to increase its funding further.

Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at ...

Article originally published by. FE fundinfo is not responsible for its content or accuracy and may not share the author’s views. News and research are not personal recommendations to deal. All ...

When Page Campbell’s doctor recommended she try an injectable prescription drug called Wegovy to lose weight before scheduling bariatric surgery, she readily agreed. “I’ve struggled with my weight for ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.